品牌咨询
联系方式
公司地址
苏州工业园区生物纳米园A4#216
联系电话
4000-520-616 / 18915418616
传真号码
0512-67156496
电子邮箱
info@ebiomall.com
公司网址
https://www.ebiomall.com

Glen research/dT-PACE Phosphoramidite/1kit/10-1170-10E

价格
¥42500.00
货号:10-1170-10E
浏览量:127
品牌:Glen research
服务
全国联保
正品保证
正规发票
签订合同
商品描述
Technical Documents
Description
Details
Intellectual Property
Dilution/Coupling Data

Technical Documents

Safety Data Sheet

PACE.pdf

Glen Report 20.21: Phosphonoacetate (PACE) Oligonucleotides Introduction

Glen Report 20.22: Synthesis, Cleavage and Deprotection of PACE Oligonucleotides

Glen Report 21.26: Non-Aqueous Oxidation for PACE Chemistry

Glen Report 30.13: Significant Improvement of CRISPR Specificity with 2"-OMe-PACE Modifications

Glen Report 30.14: Use of 2"-OMe-PACE Monomers During Oligo Synthesis


Description

Phosphonoacetate (PACE) modified oligonucleotides show great potential as biological modifiers in a wide variety of research applications. PACE monomers are part of a family of Phosphonocarboxylate monomers. The monomers can be easily incorporated into complex oligonucleotides and are compatible with a wide variety of other sugar or heterobase modifications. PACE DNA can be conjugated through the carboxylic acid functional group. They have been shown to be active in siRNA duplexes and accelerate the initial rate of cleavage by RNase H-1 when incorporated with phosphorothioates. However, the most interesting observation to date is that they exhibit an unprecedented enhancement in penetration of cultured cells. T

he phosphonoacetates are fully soluble in acetonitrile at a recommended concentration of 0.1M and are compatible with standard DNA synthesizers. A recommended coupling time of 33.3 minutes with 1H-Tetrazole is necessary when using the standard protocol. A modified LV cycle for AB instruments that reduces coupling time to 15 minutes with 1H-Tetrazole is available on our website. Oxidation must precede capping in the synthesis cycle. Reagents for oxidation depend on the type of synthesis. For fully modified oligos, we recommend the non-aqueous oxidizer camphorsulfonyloxaziridine (CSO) as a 0.1M solution. For mixed phosphodiester and phosphonoacetate modified oligos, a 0.5M CSO solution is recommended. Low water oxidizer, 40-4032, is an alternative oxidizing reagent although it has been reported that this can result in conversion of a small percentage of the phosphonoacetate to the phosphodiester. We also recommend the use of the Cap Mix B with DMAP (40-4020) instead of the standard Cap Mix B containing 1-Methylimidazole. 

The standard protocol for cleavage and deprotection requires a two step method with pretreatment using 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) and subsequent cleavage using methylamine. The DBU is used to deprotect the dimethylcyanoethyl (DMCE) protecting groups and to prevent alkylation of the bases during deprotection. Cleavage with 40% methylamine in water is recommended and we have also had good results when using AMA deprotection.

Details

Usage

  • Coupling: 33 minutes with 1H-Tetrazole Activator.||Synthesis: Oxidize before capping.Use either low water, low iodine oxidizer (Cat.# 40-4032-xx) or 10-camphorsulfonyloxaziridine (CSO) in acetonitrile.When CSO is used, extend the oxidation time to 3 minutes.Use 0.5M CSO when oxidizing mixed PACE/phosphodiester linkages.When oxidizing only PACE linkages, 0.1 M CSO can be used.For Cap Mix B, use 6.5% DMAP in THF (Cat.# 40-4020-xx).An example of a PACE cycle for AB synthesizers can be seen at:|http://www.glenresearch.com/Technical/PACE_cycle.pdf
  • Deprotection: Pretreat synthesis column with 1.5% DBU in anhydrous acetonitrile for 60 minutes (syringe method).Wash with acetonitrile and dry with argon.Deprotect with 40% Methylamine for 20 minutes at 55°C.
Specifications
DiluentAnhydrous Acetonitrile
StorageFreezer storage, -10 to -30°C, dry
Stability2-3 days

Intellectual Property

These products are covered by patents, US 6,693,187 and 7,067,641, and patents pending owned by Metasense Technologies. Purchase of all or any of these products includes a limited license to use the products solely for the manufacture of oligonucleotides for research use only. This license specifically excludes the use of the product or oligonucleotides containing the product for: (a) therapeutic or diagnostic applications (including kits, pools, libraries and other products or services that incorporate oligonucleotides containing the product), (b) any in vivo toxicity/safety study in support of an investigational new drug application (or foreign counterpart), or (c) resale (including sale of kits, pools, libraries and other products or services that incorporate the product or oligonucleotides containing the product). If such activities have commercial application, a separate license is required from Metasense Technologies. Neither the product nor any product created through its use may be used in human clinical trials.A simple agreement must be signed before end-users and custom oligo services may purchase these products for use as defined above.

Dilution/Coupling Data

The table below show pack size data and, for solutions, dilution and approximate coupling based on normal priming procedures.

ABI 392/394

Catalog #Pack SizeGrams/Pack0.1M Dil. (mL)Approximate Number of Additions
LV40LV20040nm0.2μm1μm10μm
10-1170-020.25 g.25grams3.078953.433.3824.2717.84.45
10-1170-050.5 g.5grams6.14191.33114.871.7552.1838.279.57
10-1170-101.0 g1grams12.27395.67237.4148.38107.9179.1319.78

Expedite

Catalog #Pack SizeGrams/PackDilution (mL)Approximate Number of Additions
Molarity50nm0.2μm1μm15μm
10-1170-020.25 g.25grams4.580.0785.253.2538.735.33
10-1170-050.5 g.5grams9.160.07176.8110.580.3611.05
10-1170-101.0 g1grams18.320.07360225163.6422.5

Glen research表观遗传学是生物学和癌症研究中发展最快的领域之一。虽然基本的遗传密码定义了合成哪些蛋白质和基因产物,但表观遗传控制定义了它们何时何地表达。基因表达的这种动态控制对于X染色体失活,胚胎发生,细胞分化至关重要,并且似乎是记忆形成和突触可塑性的组成部分。在2009年,两份报告1,2  中所述5-羟甲基-2'-脱氧胞苷的发现(HMDC),浦肯野神经元和胚胎干细胞的新颖的DC修饰。后来,第三份报告发现这种修饰在与较高认知功能相关的脑组织中高度丰富。3 dC修饰是通过α-酮戊二酸依赖性十一种11易位(TET)酶的作用产生的,该酶将5-Me-dC氧化为hmdC。这一发现激发了关于可能通过例如碱基切除修复(BER)借助专门的DNA糖基化酶发生的活性脱甲基途径的讨论。或者,可以设想一种方法,其中将hmdC的羟甲基进一步氧化为5-甲酰基-dC(fdC)或5-羧基-dC(cadC),然后消除甲酸或二氧化碳4,5。Glen Research自成立以来就一直为这项研究提供支持,为合成包含所有新dC衍生物-hmdC,fdC和cadC的寡核苷酸提供了基础。第一代hmdC亚磷酰胺已被广泛接受,但需要相当苛刻的脱保护条件。因此,介绍了由Carell和同事开发的与UltraMild脱保护兼容的第二代构建基(5-Hydroxymethyl-dC II)。6  5-甲酰基-dC III旨在满足制备包含所有甲基化变体的寡核苷酸的所有要求。